Is EVMN or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Maze Therapeutics N/A -34.94% -30.18%

Does the media prefer EVMN or MAZE?

In the previous week, Evommune had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 4 mentions for Evommune and 1 mentions for Maze Therapeutics. Evommune's average media sentiment score of -0.38 beat Maze Therapeutics' score of -1.05 indicating that Evommune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Is EVMN or CGEM more profitable?

Cullinan Therapeutics' return on equity of -52.89% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A -62.63% -40.55% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media prefer EVMN or CGEM?

In the previous week, Evommune and Evommune both had 4 articles in the media. Cullinan Therapeutics' average media sentiment score of 0.69 beat Evommune's score of -0.38 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ORIC or EVMN more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Evommune N/A -62.63% -40.55%

Does the media refer more to ORIC or EVMN?

In the previous week, Evommune had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Evommune and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Evommune's score of -0.38 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better earnings & valuation, VOR or EVMN?

Vor Biopharma has higher earnings, but lower revenue than Evommune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Evommune $13M 26.35 -$68.87M -$11.03 N/A

Is VOR or EVMN more profitable?

Vor Biopharma's return on equity of 0.00% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Evommune N/A -62.63% -40.55%

Does the media prefer VOR or EVMN?

In the previous week, Evommune had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Evommune and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 beat Evommune's score of -0.38 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to RARE or EVMN?

In the previous week, Ultragenyx Pharmaceutical had 35 more articles in the media than Evommune. MarketBeat recorded 39 mentions for Ultragenyx Pharmaceutical and 4 mentions for Evommune. Ultragenyx Pharmaceutical's average media sentiment score of 0.71 beat Evommune's score of -0.38 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 12 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Evommune (EVMN) Competitors

$9.44 -0.21 (-2.18%)

As of 03:58 PM Eastern

Compare

EVMN vs. MAZE, CGEM, ORIC, VOR, and RARE

Should you buy Evommune stock or one of its competitors? Evommune's main competitors and comparable companies include Maze Therapeutics (MAZE), Cullinan Therapeutics (CGEM), Oric Pharmaceuticals (ORIC), Vor Biopharma (VOR), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evommune compare to Maze Therapeutics?

Evommune (NYSE:EVMN) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Evommune has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	26.35	-$68.87M	-$11.03	N/A
Maze Therapeutics	$20M	62.19	-$131.12M	-$2.52	N/A

Evommune presently has a consensus price target of $33.33, suggesting a potential upside of 253.11%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 194.77%. Given Evommune's higher probable upside, research analysts clearly believe Evommune is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

Maze Therapeutics' return on equity of -34.94% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Maze Therapeutics	N/A	-34.94%	-30.18%

In the previous week, Evommune had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 4 mentions for Evommune and 1 mentions for Maze Therapeutics. Evommune's average media sentiment score of -0.38 beat Maze Therapeutics' score of -1.05 indicating that Evommune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maze Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Maze Therapeutics beats Evommune on 7 of the 13 factors compared between the two stocks.

How does Evommune compare to Cullinan Therapeutics?

Evommune (NYSE:EVMN) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Evommune and Evommune both had 4 articles in the media. Cullinan Therapeutics' average media sentiment score of 0.69 beat Evommune's score of -0.38 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	26.35	-$68.87M	-$11.03	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Evommune currently has a consensus price target of $33.33, indicating a potential upside of 253.11%. Cullinan Therapeutics has a consensus price target of $33.00, indicating a potential upside of 54.57%. Given Evommune's higher probable upside, equities analysts plainly believe Evommune is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cullinan Therapeutics' return on equity of -52.89% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	-62.63%	-40.55%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

86.3% of Cullinan Therapeutics shares are held by institutional investors. 31.1% of Evommune shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Evommune beats Cullinan Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Evommune compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 31.1% of Evommune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Evommune had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Evommune and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Evommune's score of -0.38 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Oric Pharmaceuticals currently has a consensus target price of $19.60, suggesting a potential upside of 54.70%. Evommune has a consensus target price of $33.33, suggesting a potential upside of 253.11%. Given Evommune's higher probable upside, analysts clearly believe Evommune is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Oric Pharmaceuticals' return on equity of -35.35% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Evommune	N/A	-62.63%	-40.55%

Evommune has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Evommune	$13M	26.35	-$68.87M	-$11.03	N/A

Summary

Oric Pharmaceuticals and Evommune tied by winning 7 of the 14 factors compared between the two stocks.

How does Evommune compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

97.3% of Vor Biopharma shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 31.1% of Evommune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vor Biopharma's return on equity of 0.00% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Evommune	N/A	-62.63%	-40.55%

In the previous week, Evommune had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Evommune and 2 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 beat Evommune's score of -0.38 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vor Biopharma currently has a consensus price target of $43.38, indicating a potential upside of 98.15%. Evommune has a consensus price target of $33.33, indicating a potential upside of 253.11%. Given Evommune's higher probable upside, analysts clearly believe Evommune is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Vor Biopharma has higher earnings, but lower revenue than Evommune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Evommune	$13M	26.35	-$68.87M	-$11.03	N/A

Summary

Vor Biopharma beats Evommune on 6 of the 11 factors compared between the two stocks.

How does Evommune compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 31.1% of Evommune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical currently has a consensus price target of $34.58, indicating a potential upside of 136.03%. Evommune has a consensus price target of $33.33, indicating a potential upside of 253.11%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Evommune	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Evommune has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Evommune's return on equity of -62.63% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Evommune	N/A	-62.63%	-40.55%

In the previous week, Ultragenyx Pharmaceutical had 35 more articles in the media than Evommune. MarketBeat recorded 39 mentions for Ultragenyx Pharmaceutical and 4 mentions for Evommune. Ultragenyx Pharmaceutical's average media sentiment score of 0.71 beat Evommune's score of -0.38 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Evommune has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.15	-$575M	-$5.84	N/A
Evommune	$13M	26.35	-$68.87M	-$11.03	N/A

Summary

Evommune beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$342.58M	$3.92B	$7.26B	$23.13B
Dividend Yield	N/A	3.64%	2.53%	3.62%
P/E Ratio	-0.86	14.25	275.57	28.32
Price / Sales	26.35	1,580.84	693.66	88.37
Price / Cash	N/A	41.62	28.04	19.33
Price / Book	1.45	15.60	10.56	4.73
Net Income	-$68.87M	-$22.86M	$3.49B	$1.07B
7 Day Performance	-9.38%	-1.22%	-0.24%	-0.96%
1 Month Performance	-32.04%	-4.53%	-2.79%	-4.02%
1 Year Performance	N/A	38.35%	18.26%	8.68%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	3.2611 of 5 stars	$9.44 -2.2%	$33.33 +253.1%	N/A	$342.58M	$13M	N/A	48	Analyst Forecast
MAZE Maze Therapeutics	2.0933 of 5 stars	$23.44 -2.0%	$66.00 +181.6%	-1.8%	$1.33B	$167.50M	N/A	141	Negative News
CGEM Cullinan Therapeutics	3.2086 of 5 stars	$21.36 +3.5%	$33.00 +54.5%	+240.0%	$1.33B	N/A	N/A	109	Gap Up
ORIC Oric Pharmaceuticals	2.3545 of 5 stars	$12.88 +2.7%	$19.60 +52.2%	+21.1%	$1.30B	N/A	N/A	111	Positive News
VOR Vor Biopharma	1.3432 of 5 stars	$21.89 -0.3%	$43.38 +98.1%	-21.4%	$1.30B	N/A	N/A	76	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. MAZE, CGEM, ORIC, VOR, and RARE

How does Evommune compare to Maze Therapeutics?

Summary

How does Evommune compare to Cullinan Therapeutics?

Summary

How does Evommune compare to Oric Pharmaceuticals?

Summary

How does Evommune compare to Vor Biopharma?

Summary

How does Evommune compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. MAZE, CGEM, ORIC, VOR, and RARE

How does Evommune compare to Maze Therapeutics?

Which has higher earnings & valuation, EVMN or MAZE?

Do analysts prefer EVMN or MAZE?

Is EVMN or MAZE more profitable?

Does the media prefer EVMN or MAZE?

Summary

How does Evommune compare to Cullinan Therapeutics?

Does the media prefer EVMN or CGEM?

Which has stronger earnings and valuation, EVMN or CGEM?

Do analysts recommend EVMN or CGEM?

Is EVMN or CGEM more profitable?

Do institutionals & insiders believe in EVMN or CGEM?

Summary

How does Evommune compare to Oric Pharmaceuticals?

Do institutionals and insiders hold more shares of ORIC or EVMN?

Does the media refer more to ORIC or EVMN?

Do analysts rate ORIC or EVMN?

Is ORIC or EVMN more profitable?

Which has preferable earnings & valuation, ORIC or EVMN?

Summary

How does Evommune compare to Vor Biopharma?

Do institutionals and insiders believe in VOR or EVMN?

Is VOR or EVMN more profitable?

Does the media prefer VOR or EVMN?

Do analysts prefer VOR or EVMN?

Which has better earnings & valuation, VOR or EVMN?

Summary

How does Evommune compare to Ultragenyx Pharmaceutical?

Do insiders & institutionals believe in RARE or EVMN?

Do analysts prefer RARE or EVMN?

Is RARE or EVMN more profitable?

Does the media refer more to RARE or EVMN?

Which has stronger earnings and valuation, RARE or EVMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools